| Open Document File Size: 187,93 KBShare Result on Facebook
Country United States / / IndustryTerm immediate‐release products / treatment of insomnia / zolpidem‐containing products / certain immediate‐release zolpidem products / Online Regular Mail / extended‐release products / outpatient retail pharmacies / prescribing the lower doses―5 mg for immediate‐release products / / MedicalCondition insomnia / headache / zolpidem‐containing insomnia / Drowsiness / widely prescribed insomnia / patient’s insomnia / prescription insomnia / / Organization U.S. Food and Drug Administration / FDA / / / Product secobarbital sodium / butabarbital sodium / Restoril / Benadryl / Placidyl / Doral / Butisol sodium / estazolam / Lunesta / Rozerem / zolpidem tartrate / Prosom / ethchlorvynol / temazepam / Sonata / Unisom / doxepin hydrochloride / triazolam / Ambien CR / Ambien / Dalmane / flurazepam hydrochloride / Halcion / zolpidem / zaleplon / / ProvinceOrState Maryland / / PublishedMedium the Medication Guide / / Technology simulation / /
SocialTag |
FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist)